Wong, M. M. Y. et al. Anemia and iron deficiency amongst continual kidney illness Phases 3–5ND sufferers within the continual kidney illness outcomes and follow patterns research: Typically unmeasured, variably handled. Clin. Kidney J. 13, 613–624 (2020).
Gafter-Gvili, A., Schechter, A. & Rozen-Zvi, B. Iron deficiency anemia in continual kidney illness. Acta Haematol. 142, 44–50 (2019).
KIDGO Work Group and Kidney Illness: Enhancing World Outcomes (KDIGO) Anemia Work Group. KDIGO Scientific Follow Guideline for Anemia in Power Kidney Illness. Kidney Worldwide Dietary supplements Vol. 2. http://kdigo.org/home/guidelines/anemia-in-ckd/; http://linkinghub.elsevier.com/retrieve/pii/S2157171615310777 (2012).
Ghafourian, Okay., Shapiro, J. S., Goodman, L. & Ardehali, H. Iron and coronary heart failure: Prognosis, therapies, and future instructions. JACC Fundamental Transl. Sci. 5, 300–313 (2020).
Macdougall, I. et al. Intravenous iron in sufferers present process upkeep hemodialysis. N. Engl. J. Med. 380, 447–458 (2019).
Bhandari, S. et al. Security and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in sufferers with continual kidney illness: The FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol. Dial. Transplant. https://doi.org/10.1093/ndt/gfaa011 (2020).
Kuo, Okay. L., Hung, S. C., Wei, Y. H. & Tarng, D. C. Intravenous iron exacerbates oxidative DNA harm in peripheral blood lymphocytes in continual hemodialysis sufferers. J. Am. Soc. Nephrol. 19, 1817–1826 (2008).
Kuo, Okay. L., Hung, S. C., Lee, T. S. & Tarng, D. C. Iron sucrose accelerates early atherogenesis by growing superoxide manufacturing and upregulating adhesion molecules in CKD. J. Am. Soc. Nephrol. 25, 2596–2606 (2014).
Scheiber-Mojdehkar, B., Lutzky, B., Schaufler, R., Sturm, B. & Goldenberg, H. Non-transferrin-bound iron within the serum of hemodialysis sufferers who obtain ferric saccharate: No correlation to peroxide era. J. Am. Soc. Nephrol. 15, 1648–1655 (2004).
Kassianides, X., Hazara, A. M. & Bhandari, S. Enhancing the security of intravenous iron remedies for sufferers with continual kidney illness. Knowledgeable Opin. Drug Saf. 20, 23–35 (2021).
Bhandari, S., Pereira, D. I. A., Chappell, H. F. & Drakesmith, H. Intravenous irons: From primary science to medical follow. Prescribed drugs 11, 82 (2018).
Jahn, M. R. et al. A comparative research of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a brand new intravenous iron preparation and its medical implications. Eur. J. Pharm. Biopharm. 78, 480–491 (2011).
Pai, A. B., Conner, T., McQuade, C. R., Olp, J. & Hicks, P. Non-transferrin sure iron, cytokine activation and intracellular reactive oxygen species era in hemodialysis sufferers receiving intravenous iron dextran or iron sucrose. Biometals 24, 603–613 (2011).
Agarwal, R., Rizkala, A. R., Kaskas, M. O., Minasian, R. & Trout, J. R. Iron sucrose causes higher proteinuria than ferric gluconate in non-dialysis continual kidney illness. Kidney Int. 72, 638–642 (2007).
Garbowski, M. W. et al. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica 106, 2885–2896 (2020).
Panth, N., Paudel, Okay. R. & Parajuli, Okay. Reactive oxygen species: A key hallmark of heart problems. Adv. Med. 2016, 1–12 (2016).
Kraml, P. The position of iron within the pathogenesis of atherosclerosis. Physiol. Res. 66, S55–S67 (2017).
Yoo, J. H. et al. Oxidative standing in iron-deficiency anemia. J. Clin. Lab. Anal. 23, 319–323 (2009).
Nuhu, F. & Bhandari, S. Oxidative stress and cardiovascular problems in continual kidney illness, the affect of anaemia. Prescribed drugs 11, 103 (2018).
Bhandari, S., Allgar, V., Lamplugh, A., MacDougall, I. C. & Kalra, P. A. Protocol and Baseline knowledge of a multicentre potential double-blinded randomized research of intravenous iron on useful standing in sufferers with continual kidney illness. Am. J. Nephrol. 51, 493–500 (2020).
Bhandari, S., Allgar, V., Lamplugh, A., Macdougall, I. & Kalra, P. A. A multicentre potential double blinded randomised managed trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron poor however not anaemic sufferers with continual kidney illness on useful standing. BMC Nephrol. 22 (2021).
Kassianides, X., Hazara, A. M., Macdougall, I. C., Kalra, P. A. & Bhandari, S. The affect of intravenous iron on renal damage and performance markers in sufferers with continual kidney illness and iron deficiency with out anemia. Kidney Int. Rep. (2021) (in press).
del Vecchio, L. et al. Intravenous iron remedy and the cardiovascular system: Dangers and advantages. Clin. Kidney J. 14, 1067–1076 (2021).
Aljwaid, H., White, D. L., Collard, Okay. J., Moody, A. J. & Pinkney, J. H. Non-transferrin-bound iron is related to biomarkers of oxidative stress, irritation and endothelial dysfunction in sort 2 diabetes. J. Diabetes Complicat. 29, 943–949 (2015).
Kuo, Okay. L. et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and elevated cardiovascular threat amongst hemodialysis sufferers. PLoS One 7, e50295 (2012).
Fütterer, S., Andrusenko, I., Kolb, U., Hofmeister, W. & Langguth, P. Structural characterization of iron oxide/hydroxide nanoparticles in 9 totally different parenteral medication for the therapy of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J. Pharm. Biomed. Anal. 86, 151–160 (2013).
Ganguli, A. et al. Lipid peroxidation merchandise formation with numerous intravenous iron preparations in continual kidney illness. Ren. Fail. 31, 106–110 (2009).
Connor, J. R., Zhang, X., Nixon, A. M., Webb, B. & Perno, J. R. Comparative analysis of nephrotoxicity and administration by macrophages of intravenous pharmaceutical iron formulations. PLoS One 10, e0125272 (2015).
Kassianides, X., Gordon, A., Sturmey, R. & Bhandari, S. The comparative results of intravenous iron on oxidative stress and irritation in sufferers with continual kidney illness and iron deficiency: A randomized managed pilot research. Kidney Res. Clin. Pract. 40, 89–98 (2021).
Meroño, T. et al. Oxidative stress, HDL performance and results of intravenous iron administration in girls with iron deficiency anemia. Clin. Nutr. 36, 552–558 (2017).
Martin-Malo, A. et al. Results of intravenous iron on mononuclear cells throughout the haemodialysis session. Nephrol. Dial. Transplant. 27, 2465–2471 (2012).
Fell, L. H. et al. Distinct immunologic results of various intravenous iron preparations on monocytes. Nephrol. Dial. Transplant. 29, 809–822 (2014).
Malindretos, P. et al. Sluggish intravenous iron administration doesn’t irritate oxidative stress and inflammatory biomarkers throughout hemodialysis: A comparative research between iron sucrose and iron dextran. Am. J. Nephrol. 27, 572–579 (2007).
Drüeke, T. et al. Iron remedy, superior oxidation protein merchandise, and carotid artery intima-media thickness in end-stage renal illness. Circulation 106, 2212–2217 (2002).
Tvaroška, I., Selvaraj, C. & Koča, J. Selectins—The 2 Dr. Jekyll and Mr. Hyde faces of adhesion molecules—A assessment. Molecules 25, 2835 (2020).
Kartikasari, A. E. R. et al. Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24, 2257–2262 (2004).
Kartikasari, A. E. R. et al. Iron enhances endothelial cell activation in response to Cytomegalovirus or Chlamydia pneumoniae an infection. Eur. J. Clin. Investig. 36, 743–752 (2006).
Taylor, D., Bhandari, S. & Seymour, A. M. L. Mitochondrial dysfunction in uremic cardiomyopathy. Am. J. Physiol. Renal Physiol. 308, F579–F587 (2015).
Nuhu, F., Seymour, A. M. & Bhandari, S. Impression of intravenous iron on oxidative stress and mitochondrial operate in experimental continual kidney illness. Antioxidants 8, 498 (2019).
Toblli, J. E., Lombraña, A., Duarte, P. & di Gennaro, F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic sufferers with continual coronary heart failure and renal insufficiency. J. Am. Coll. Cardiol. 50, 1657–1665 (2007).
Toblli, J. E., di Gennaro, F. & Rivas, C. Adjustments in echocardiographic parameters in iron deficiency sufferers with coronary heart failure and continual kidney illness handled with intravenous iron. Coronary heart Lung Circ. 24, 686–695 (2015).
Charles-Edwards, G. et al. Impact of iron isomaltoside on skeletal muscle energetics in sufferers with continual coronary heart failure and iron deficiency: FERRIC-HF II randomized mechanistic trial. Circulation 139, 2386–2398 (2019).
Kalra, P. A. et al. NIMO-CKD-UK: An actual-world, observational research of iron isomaltoside in sufferers with iron deficiency anaemia and continual kidney illness. BMC Nephrol. 21, 539 (2020).
